A detailed history of 683 Capital Management, LLC transactions in Immatics N.V. stock. As of the latest transaction made, 683 Capital Management, LLC holds 815,000 shares of IMTX stock, worth $9.56 Million. This represents 0.86% of its overall portfolio holdings.

Number of Shares
815,000
Previous 900,000 9.44%
Holding current value
$9.56 Million
Previous $9.46 Million 0.12%
% of portfolio
0.86%
Previous 0.81%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$9.78 - $13.49 $831,300 - $1.15 Million
-85,000 Reduced 9.44%
815,000 $9.47 Million
Q1 2024

May 15, 2024

SELL
$10.23 - $12.94 $2.05 Million - $2.59 Million
-200,000 Reduced 18.18%
900,000 $9.46 Million
Q4 2023

Feb 14, 2024

BUY
$7.36 - $10.89 $147,200 - $217,800
20,000 Added 1.85%
1,100,000 $11.6 Million
Q3 2023

Nov 14, 2023

SELL
$11.01 - $12.62 $2.97 Million - $3.41 Million
-270,000 Reduced 20.0%
1,080,000 $12.5 Million
Q2 2023

Aug 14, 2023

BUY
$5.92 - $12.72 $89,172 - $191,601
15,063 Added 1.13%
1,350,000 $15.6 Million
Q1 2023

May 15, 2023

BUY
$6.74 - $9.44 $235,475 - $329,805
34,937 Added 2.69%
1,334,937 $9.21 Million
Q4 2022

Feb 14, 2023

SELL
$8.05 - $11.58 $689,080 - $991,248
-85,600 Reduced 6.18%
1,300,000 $11.3 Million
Q2 2022

Aug 15, 2022

BUY
$6.0 - $9.37 $753,600 - $1.18 Million
125,600 Added 9.97%
1,385,600 $12.1 Million
Q1 2022

May 16, 2022

BUY
$6.64 - $12.85 $504,341 - $976,021
75,955 Added 6.41%
1,260,000 $10.1 Million
Q1 2021

May 17, 2021

BUY
$10.24 - $14.6 $963,020 - $1.37 Million
94,045 Added 8.63%
1,184,045 $13.3 Million
Q4 2020

Feb 16, 2021

BUY
$9.67 - $12.05 $386,800 - $482,000
40,000 Added 3.81%
1,090,000 $11.8 Million
Q3 2020

Nov 16, 2020

BUY
$8.73 - $15.15 $9.17 Million - $15.9 Million
1,050,000 New
1,050,000 $11.1 Million

Others Institutions Holding IMTX

About Immatics N.V.


  • Ticker IMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,227,000
  • Market Cap $894M
  • Description
  • Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...
More about IMTX
Track This Portfolio

Track 683 Capital Management, LLC Portfolio

Follow 683 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on 683 Capital Management, LLC with notifications on news.